Chiroscience rights issue calms frenzy
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biotechnology company Chiroscience completed a remarkable 48 hours on the stock market yesterday, with its shares more than doubling at one stage before beating a partial retreat on the announcement that the company was planning a pounds 40m rights issue at an unspecified future date.
In heavy trading, the shares surged from 400p to 588p at one stage, before falling back to close at 460p. More than 4 million shares changed hands, 12 times the daily average. The volatile performance followed a 117.5p rise on Thursday.
The excitement was caused, analysts said, by the announced scrapping of an alliance with Pharmacia & Upjohn to develop a purified epidural manufactured by Swedish drugs group Astra.
The drug, Levobupivacaine, is Chiroscience's leading treatment in development. Like other drugs the company is developing it is a "chiral", or single isomer version of an existing drug. Chiroscience believes these purer drugs function better than existing treatments.
Going it alone could boost revenues by a sizeable amount, but it also increases the risks taken by the company. When biotechnology companies sell drugs on to big pharmaceuticals they normally receive royalties of between 10 and 15 per cent. On their own they keep all the revenues but have to pay for development and marketing costs.
Both Chiroscience and its rival British Biotech are developing so-called matrix metalloproteinase inhibitors, a class of compound that analysts say has shown great promise in cancer and arthritis treatments.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments